drugset
drugset / Trial / NCT04330248

A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants

NCT04330248 ↗

Phase 1 Completed 15 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
NaSingle-groupOpen-labelOther

Summary

The main purpose of this study is to evaluate the effect of multiple doses of carbamazepine (a strong inducer of cytochrome P450 \[CYP\]3A4 and a weak inducer of CYP2C9) on the pharmacokinetics of a single oral dose of erdafitinib in healthy adult participants.

Timeline

Start
2020-03-31
Primary completion
2022-06-14
Completion
2022-06-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbamazepine Small molecule — Oral
Subject Erdafitinib Small molecule — Oral

Indications

No indication recorded.